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Until about 40 years ago, very little was known about the etiology of 
hepatocellular carcinoma, except that it was associated with liver 
cirrhosis. During the 1970s, epidemiological studies, first in Africa 
(1) and Asia (2) and later in Europe (3), firmly documented an 
important role of chronic infection with hepatitis B virus (HBV) in 
the etiology of hepatocellular carcinoma. About 10 years later, 
studies that relied on clinical case series (4) followed by formal case–
control studies in Africa (5) and in Europe (6) showed that chronic 
infection with hepatitis C virus (HCV) was also strongly linked to 
hepatocellular carcinoma. Both HBV and HCV have been declared 
to be carcinogenic to humans by the International Agency for 
Research on Cancer (IARC) (7). Meanwhile, evidence has emerged 
that tobacco smoking is strongly related to hepatocellular carcinoma 
(8). Following a series of publications with converging findings, 
IARC has included hepatocellular carcinoma among the types of 
cancer that are causally associated with tobacco smoking (9). Alcohol 
intake, mostly by causing cirrhosis, is also an established liver carcin-
ogen (10); indeed, heavy, but not moderate, alcohol consumption 
has been strongly associated with the risk of the disease (11). Finally, 
there is considerable evidence that obesity is an important factor in 
the etiology of hepatocellular carcinoma (12), whereas coffee 
drinking has been reported to reduce the risk of the disease (13,14).
Substantial progress has been made to identify exposures that 
strongly increase the risk of hepatocellular carcinoma and to quantify 
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 Background To date, no attempt has been made to systematically determine the apportionment of the hepatocellular carci-
noma burden in Europe or North America among established risk factors.
 Methods Using data collected from 1992 to 2006, which included 4 409 809 person-years in the European Prospective 
Investigation into Cancer and nutrition (EPIC), we identified 125 case patients with hepatocellular carcinoma, of 
whom 115 were matched to 229 control subjects. We calculated odds ratios (ORs) for the association of docu-
mented risk factors for hepatocellular carcinoma with incidence of this disease and estimated their importance 
in this European cohort.
 Results Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (OR = 9.10, 95% confidence interval [CI] = 
2.10 to 39.50 and OR = 13.36, 95% CI = 4.11 to 43.45, respectively), obesity (OR = 2.13, 95% CI = 1.06 to 4.29), 
former or current smoking (OR = 1.98, 95% CI = 0.90 to 4.39 and OR = 4.55, 95% CI = 1.90 to 10.91, respectively), 
and heavy alcohol intake (OR = 1.77, 95% CI = 0.73 to 4.27) were associated with hepatocellular carcinoma. 
Smoking contributed to almost half of all hepatocellular carcinomas (47.6%), whereas 13.2% and 20.9% were 
attributable to chronic HBV and HCV infection, respectively. Obesity and heavy alcohol intake contributed 16.1% 
and 10.2%, respectively. Almost two-thirds (65.7%, 95% CI = 50.6% to 79.3%) of hepatocellular carcinomas can 
be accounted for by exposure to at least one of these documented risk factors.
 Conclusions Smoking contributed to more hepatocellular carcinomas in this Europe-wide cohort than chronic HBV and HCV 
infections. Heavy alcohol consumption and obesity also contributed to sizeable fractions of this disease burden. 
These contributions may be underestimates because EPIC volunteers are likely to be more health conscious 
than the general population.
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the strength of their association with the disease. However, there 
has been no systematic attempt to estimate, in a population-based 
multinational cohort, the fraction of the hepatocellular carcinoma 
burden that is attributable to all established risk factors and, thus, 
amendable to primary prevention. This fraction depends on the 
prevalence of the risk factors in a given population, which can vary 
over place and time. In this article, we have generated conservative 
estimates of the quantitative importance of the indicated risk fac-
tors for hepatocellular carcinoma in the Europe-wide cohort of the 
European Prospective Investigation into Cancer and nutrition 
(EPIC). No previous cohort-based investigation has evaluated in 
the same dataset, the whole range of factors that have been docu-
mented to contribute to the etiology of hepatocellular carcinoma 
in Europe, North America, or Australia.
Methods
EPIC is a large cohort study that was established to investigate the 
role of biological, dietary, lifestyle, and environmental factors in 
the etiology of cancer and other chronic diseases (15). Approximately 
500 000 healthy males and females, aged 25–70 years, were 
recruited between 1992 and 2000 in 23 centers from 10 European 
countries (Denmark, France, Germany, Greece, Italy, the 
Netherlands, Norway, Spain, Sweden, and the United Kingdom). 
Most of the participants were selected from the general adult 
population, but some centers recruited members of health insur-
ance services (France; women only) or breast cancer screening 
participants (Utrecht, Florence; women only). In Oxford, vegetar-
ians were recruited in addition to participants from the general 
population, whereas in Italy and Spain, some cohorts included 
members of blood donor associations. Details of the EPIC study 
have been published (15).
The protocol of the EPIC study was approved by the Ethical 
Review Board at IARC and the ethical committees of the partici-
pating centers. All participants provided informed consent, and 
procedures were in line with the Helsinki Declaration for human 
rights.
Dietary, Lifestyle, Anthropometric, and Medical Variables
At enrollment, usual dietary intakes were assessed using food- 
frequency questionnaires. For some centers, we also used records 
of food and beverage intake over 7 or 14 days that were developed 
and validated by each center (16). Daily intakes of foods and 
beverages (including coffee) were calculated in grams. Ethanol 
intake (g/d) and total energy intake (kcal/d) were calculated using 
the EPIC Nutrient Database (17).
We used a questionnaire at enrollment to record sociodemo-
graphic data (including education) and data on lifestyle (including 
smoking) and medical history. From these data, we calculated 
energy expenditure related to professional, domestic, and leisure 
activities and created an index for overall daily physical activity 
with four categories: inactive, moderately inactive, moderately 
active, and active (18).
At enrollment, waist and hip circumferences, weight, and 
height were measured according to a common protocol with 
slight variations among centers. We corrected body weights and 
waist circumference data to reduce heterogeneity associated with 
differences in clothing (19), and we calculated body mass index 
(BMI in kg/m2).
Hepatitis Virus Testing
Blood samples from the majority of the participants were collected 
at recruitment and stored at 2196°C in liquid nitrogen. Serum 
levels of hepatitis B surface antigen (HbsAg) and antibodies to 
hepatitis C virus (anti-HCV) were determined at the Centre de 
Biologie République laboratory in Lyon (France). The 
ARCHITECT chemiluminescent microparticle immunoassay 
(CMIA) HbsAg assay (Abbott Diagnostics Division, Lyon, France) 
and the ARCHITECT CMIA anti-HCV assay (Abbott Diagnostics 
Division) were used to evaluate the presence of HbsAg and of 
anti-HCV antibodies, respectively. The laboratory personnel 
were blinded as to the disease status of the subjects whose blood 
samples they analyzed. According to manufacturer’s specifica-
tions, specimens with HbsAg concentrations that were 0.05 
International Units per milliliter or higher were considered to be 
from HBV-positive patients, whereas specimens with anti-HCV 
antibodies were considered to be from HCV-positive patients 
when the relative light units generated from the specimen were 
CONTEXT AND CAVEATS
Prior knowledge
Chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus 
(HCV) infection, smoking, obesity, and alcohol intake have been 
identified as exposures that strongly increase risk of hepatocellular 
carcinoma, but the contribution of each risk factor to the disease 
burden in Europe had not been estimated.
Study design
Using data from the European Prospective Investigation into 
Cancer and nutrition (EPIC) from 1992 to 2006, 115 patients with 
hepatocellular carcinoma were matched to 229 control subjects. 
Serum samples were tested for indications of HBV or HCV infec-
tion. The authors calculated adjusted odds ratios as estimates of 
the incidence rate ratios for the evaluated factors and the popula-
tion attributable fraction of hepatocellular carcinoma for the pres-
ence of each risk factor.
Contribution
Obesity, former or current smoking, and heavy alcohol intake were 
all associated with risk of hepatocellular carcinoma, and chronic 
HBV or HCV infection were especially strongly associated with risk. 
In this European cohort, almost half of all hepatocellular carci-
nomas were associated with smoking (47.6%), more than a quarter 
were associated with chronic HBV (13.2%) or HCV (20.9%) infec-
tion, and many with obesity (16.1%) or heavy alcohol intake 
(10.2%).
Implication
Almost two-thirds of hepatocellular carcinomas in Europe are as-
sociated with preventable exposures that increase risk.
Limitations
No data were available for the presence of cirrhosis, diabetes, afla-
toxin exposure, or other possible factors, and interactions among 
the evaluated risk factors could not be examined.
From the Editors
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equal to or higher than the reference relative light units in two 
measurements.
Follow-up
Vital status, cause of death, and date of death were collected using 
record linkage with regional and/or national death registries 
(Denmark, France, Italy, the Netherlands, Norway, Spain, Sweden, 
and the United Kingdom) or by active follow-up (Germany and 
Greece). In most countries, cancer incidence was ascertained 
through record linkage with cancer registries (Denmark, Italy, the 
Netherlands, Norway, Spain, Sweden, and the United Kingdom). 
In France, Germany, and Greece, a combination of methods was 
used to determine cancer incidence, including health insurance 
records, pathology registries, and active follow-up by means of 
mailed questionnaires or telephone interviews of the participant or 
next of kin in case of a participant’s death. Incident cancers that 
were self-reported or reported by next of kin were subsequently 
verified by pathology reports, medical records, discharge diag-
noses, or death certificates. For this study, the latest dates of com-
plete information for cancer incidence and vital status ranged from 
December 2002 to December 2006 among different centers.
The Nested Case–Control Study
Ascertainment of Case Patients. We identified all case patients 
who were diagnosed with a verified liver cancer after their recruit-
ment into the study. We initially excluded 39 case patients with no 
blood samples or missing essential information and an additional 
43 case patients with prediagnosed malignancies at other sites 
or metastatic liver cancer. For each of the remaining patients 
(ICD-O-2 code C22.0), we further examined the relevant histol-
ogies and the method used for the diagnosis of hepatocellular 
carcinoma and excluded 31 patients with types of primary liver 
cancer other than hepatocellular carcinoma. Eventually, a total of 125 
incident hepatocellular carcinoma case patients were identified.
Selection of Control Subjects. For each hepatocellular carci-
noma case patient, two control subjects were chosen. For reasons 
concerning preservation of biological samples, subjects who devel-
oped any other cancer or had been used as control subjects in other 
EPIC studies were not included in the pool of eligible control 
subjects. Control subjects were required to be alive as of the time 
of the cancer diagnosis of the corresponding case patient, hence, 
length of follow-up time for the control subject was required to be 
the same as, or longer than, that for the case patient. Control 
subjects were matched with case patients for study center, sex, age 
at the time of blood collection (±12 months), date (±2 months) of 
blood collection, and time of day (±3 hours) of blood collection. 
Women were further matched by menopausal status (pre-, post-, 
or perimenopausal) and by use of exogenous hormones (oral 
contraceptives for premenopausal women and hormone replace-
ment therapy for postmenopausal women) at blood collection (yes 
or no).
For the 125 hepatocellular carcinoma case patients, we identi-
fied 250 matching control subjects, for a total of 375 subjects. 
Among those, 29 subjects (10 case patients and 19 control subjects) 
had missing values in the variables used in further analyses; two 
additional control subjects were excluded following the exclusion 
of their corresponding case patient. The remaining 344 subjects 
with complete data comprised 115 case–control sets. Of these, 114 
case–control sets relied on two matched control subjects, whereas 
one set relied on one matched control subject because the second 
control subject was excluded due to missing information on 
smoking status.
Statistical Analysis
We cross-tabulated variables by case–control status for descriptive 
purposes. Conditional logistic regression was used to estimate the 
associations between established or possible causal factors for 
hepatocellular carcinoma and hepatocellular carcinoma risk. We 
studied the following factors: chronic HBV infection (yes vs no), 
chronic HCV infection (yes vs no), BMI (obese: ≥30 kg/m2 vs not 
obese: <30 kg/m2), education (less educated vs educated at least at 
a secondary or technical school level), smoking status (current 
smokers vs nonsmokers and former smokers vs nonsmokers), usual 
ethanol intake at baseline with distinct cutoff points for men and 
women given reports (20–22) of their differential susceptibility to 
ethanol effects (for men, high: ≥40 g/d, moderate: 10 to <40 g/d, 
low: 0 to <10 g/d; for women, high: ≥20 g/d, moderate: 5 to 
<20 g/d, low: 0 to <5 g/d; 12 g of ethanol correspond approxi-
mately to one glass of alcoholic beverage) and regular coffee intake 
(low: <250 g/d vs high: ≥250 g/d; 150 g of coffee correspond 
approximately to one cup). For all indicated variables, we com-
puted odds ratio (OR) estimates by conditional logistic regression, 
initially without adjustment and subsequently after mutually con-
trolling for the above indicated variables. Additional conditional 
logistic regression models were fitted by also adjusting for total 
energy intake (continuous), physical activity (inactive or moder-
ately inactive vs moderately active or active), and both of these 
additional variables.
Because the indicated major hepatocellular carcinoma risk fac-
tors (HBV and HCV infection, tobacco smoking, alcohol con-
sumption, and obesity) are modifiable, we also estimated the 
attributable fraction per factor. The attributable fraction denotes 
the proportion of hepatocellular carcinomas in the underlying 
population that could have been avoided if the respective exposure 
were removed. We used the formula suggested by Miettinen (23) 
and extended by Bruzzi et al. (24) for case–control studies; this 
formula relies on the adjusted estimates of the odds ratios and the 
proportion of the corresponding exposures among case patients 
and is estimated as follows:
(RR 1)
,
RR
pi× −  
where p is the proportion of exposed among the case patients 
and RR is the adjusted incidence rate ratio consistently estimated 
by the adjusted odds ratio. We calculated 95% confidence intervals 
(CIs) for the attributable fractions using the bootstrap method 
(25). Because we included participants in our sample who were 
blood donors at recruitment and our sample population might thus 
lead to an underestimation of the prevalence of chronic HBV and/
or HCV infection in the general population, we also recalculated 
the attributable fractions excluding centers which relied, even par-
tially, on blood donors (all Spanish centers, and the Ragusa and 
Turin centers from Italy). Finally, we calculated the attributable 
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fractions in the subset of subjects who were not chronically 
infected by HBV or HCV.
Analyses were run in STATA statistical software (26). Two-
sided tests of statistical significance were used, and a P value less 
than .05 was considered to denote statistical significance. For 
testing the statistical significance of the estimated odds ratios, the 
Wald test was used, whereas statistical interaction between any two 
of the examined factors was tested with the likelihood ratio test.
Results
Using data collected from 1992 to 2006, which included 4 409 809 
person-years, we first examined the distribution of the incident 
case patients of hepatocellular carcinoma and their matched con-
trol subjects, by sex, age at enrollment, and country (Table 1). 
Hepatocellular carcinoma was more common among older people 
and substantially more common among men than among women. 
A meaningful comparison of incidence patterns among the coun-
tries is not possible because the population samples differ by sex, 
age, and length of follow-up. No confirmed hepatocellular carci-
noma case patients with complete information, including bio-
markers, were identified in the French and Norwegian EPIC 
cohorts, which included women only.
The distribution of the 80 male and 35 female case patients 
with incident hepatocellular carcinoma and their matched control 
subjects was next examined by status at enrollment with respect to 
established or suspected risk factors, such as chronic infection with 
HBV, chronic infection with HCV, tobacco smoking, ethanol 
intake, BMI, and coffee intake, and with respect to physical activity 
and educational level (Table 2). The patterns in this table were not 
directly interpretable because mutual confounding was not 
accounted for. Nevertheless, the overwhelming importance of 
chronic HBV or HCV infection in the etiology of hepatocellular 
carcinoma was evident, as was the important role of tobacco 
smoking. For example, 17 (14.8%) of 115 hepatocellular carci-
noma patients were HBV-infected vs six (2.6%) of 229 matched 
control subjects, and 26 (22.6%) of 115 hepatocellular carcinoma 
patients were HCV-infected compared with seven (3.1%) of 229 of 
matched control subjects. Obesity (BMI ≥ 30 kg/m2), though not 
overweight (BMI between 25 and 30 kg/m2), was positively associ-
ated with the risk of hepatocellular carcinoma, especially among 
men: 25 (31.3%) of 80 of men with hepatocellular cancer were 
obese vs 24 (15.1%) of 159 of their matched control subjects. High 
alcohol intake, but not moderate alcohol intake, also appeared to 
be positively associated with hepatocellular carcinoma risk; 27 
(23.5%) of 115 persons with hepatocellular carcinoma were heavy 
drinkers vs 26 (11.4%) of 229 of matched control subjects. By 
contrast, there was no evidence that coffee intake, educational 
level, or physical activity were major hepatocellular carcinoma risk 
factors.
We next calculated adjusted odds ratios as estimates of the cor-
responding incidence rate ratios for the evaluated factors, overall 
and by sex (Table 3). In the presence of chronic HBV or HCV 
infection, hepatocellular carcinoma risk was sharply increased (for 
Table 1. Case patients with incident hepatocellular carcinoma and their matched control subjects within the European Prospective 
Investigation into Cancer and nutrition (EPIC) study from 1992 to 2006, by sex, age at enrollment, and country*
Patient characteristic
Hepatocellular carcinoma case patients† Matched control subjects‡ All EPIC participants
No. (%) No. (%) No. (%)
Age (matched), y
 <50 8 (7.0) 16 (7.0) 209 604 (42.4)
 50 to <60 46 (40.0) 90 (39.3) 187 490 (37.9)
 ≥60 61 (53.0) 123 (53.7) 97 272 (19.7)
Sex (matched)
 Men 80 (69.6) 159 (69.4) 148 376 (30.0)
 Women 35 (30.4) 70 (30.6) 345 990 (70.0)
Recruitment center (matched)
 Denmark 31 (27.0) 61 (26.6) 56 230 (11.4)
 Germany 19 (16.5) 38 (16.6) 50 530 (10.2)
 Greece 12 (10.4) 24 (10.5) 26 429 (5.3)
 Italy 20 (17.4) 40 (17.5) 46 322 (9.4)
 Spain 7 (6.1) 14 (6.1) 40 810 (8.3)
 Sweden 16 (13.9) 32 (14.0) 49 692 (10.1)
 The Netherlands 4 (3.5) 8 (3.5) 37 171 (7.5)
 United Kingdom 6 (5.2) 12 (5.2) 81 804 (16.5)
 Franceǁ — — 69 427 (14.0)
 Norwayǁ — — 35 951 (7.3)
Total 115 (100)§ 229 (100)§ 494 366 (100)
* Only confirmed hepatocellular carcinoma case patients and subjects with complete information are included.
† After a median follow-up of 8.9 years and a total of 4 409 809 person-years.
‡ Control subjects had to be alive as of the time of diagnosis of the corresponding case patients and were matched with case patients for study center, sex, age at 
the time of blood collection (±12 months), date of blood collection (±2 months), and time of day of blood collection (±3 hours). Women were further matched by 
menopausal status (pre-, post-, or perimenopausal) and use of exogenous hormones (oral contraceptives for premenopausal women and hormone replacement 
therapy for postmenopausal women) at time of blood collection (yes or no).
§ For one hepatocellular carcinoma case patient, only one control subject was available for whom there was no missing data on the examined risk factors.
ǁ No eligible case patients were identified in the cohorts of France and Norway, which include women only.
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HBV infection, OR = 9.10, 95% CI = 2.10 to 39.50; for HCV 
infection, OR = 13.36, 95% CI = 4.11 to 43.45). A substantial and 
statistically significant increase of hepatocellular carcinoma risk 
was evident among current smokers (OR = 4.55, 95% CI = 1.90 to 
10.91) more than former smokers (OR = 1.98, 95% CI = 0.90 to 
4.39). Obesity was also positively associated with hepatocellular 
carcinoma risk, although the association was only present among 
the more numerous male subjects (among men, OR = 3.66, 95% 
CI = 1.46 to 9.14; among all subjects, OR = 2.13, 95% CI = 1.06 
to 4.29). Heavy drinkers appeared also to be at increased risk, but 
the association was not statistically significant (OR = 1.77, 95% 
CI = 0.73 to 4.27). By contrast, there was no evidence that mod-
erate consumption of alcohol, simple overweight (BMI from 25 to 
29.9 kg/m2), low educational level (less than secondary or technical 
school), or reduced coffee intake (<250 g/d) was associated with 
increased hepatocellular carcinoma risk. Adjustment for energy 
intake and/or physical activity did not noticeably change adjusted 
odds ratio estimates (data not shown). There was no statistically 
significant interaction by sex in any of the indicated associations, 
although for BMI, the P value for interaction was close to .05 
(likelihood ratio test).
We also calculated the population attributable fractions (as 
percentages) for the five most important hepatocellular carcinoma 
risk factors from both the literature and this study, that is, chronic 
HBV or HCV infection, obesity, high alcohol intake, and current 
or past tobacco smoking (Table 4). Because neither the literature 
nor our data indicated statistically significant interactions of the 
indicated five exposures with sex with respect to hepatocellular 
carcinoma occurrence, we used the overall mutually adjusted odds 
ratios from Table 3. This was particularly relevant with respect to 
obesity, for which the odds ratios associated with hepatocellular 
carcinoma appeared to differ (although not at a statistically signif-
icant level) between sexes. We estimated the prevalence of expo-
sure to the indicated risk factors from the data in our study; while 
interpreting these findings, one must consider that the EPIC 
population comprises volunteers, who are likely characterized by 
lower prevalence of these risk factors. Overall, a substantial frac-
tion (47.6%) of the burden of hepatocellular carcinoma in this 
European population was attributed to ever smoking (for current 
smoking 31.2%, 95% CI = 17.3% to 43.3%; for former smoking 
16.4%, 95% CI = 25.9% to 32.0%). Other substantial contribu-
tors were chronic HCV infection (20.9%, 95% CI = 12.8% to 
29.2%), chronic HBV infection (13.2%, 95% CI = 5.7% to 
20.3%), obesity (16.1%, 95% CI = 20.7% to 29.3%), and heavy 
alcohol intake (10.2%, 95% CI = 28.6% to 22.5%). When we 
excluded EPIC centers in which blood donors had contributed to 
the formation of the respective cohorts, the overall attributable 
fractions changed only marginally: for HBV, from 13.2% to 
12.1%; for HCV, from 20.9 % to 20.7%; for obesity, from 16.1% 
to 15.4%; for high regular alcohol intake, from 10.2% to 9.7%; for 
current smoking, from 31.2% to 33.3%; and for former smoking, 
from 16.4% to 16.8%. When we excluded subjects who were 
chronically infected with HBV or HCV, the overall attributable 
fractions were as follows: for obesity, 20.9%; for high regular 
alcohol intake, 18.0%; for current smoking, 32.2%; and for former 
smoking, 13.7%.
We also calculated the population attributable fraction of hepa-
tocellular carcinoma for the presence of at least one of the five risk 
factors indicated above (not including former smoking). This frac-
tion was 65.7% (95% CI = 50.6% to 79.3%), indicating that about 
two-thirds of hepatocellular carcinoma cases were attributable to 
established risk factors for this disease. Among hepatitis virus–
negative hepatocellular carcinoma case patients, the population 
attributable fraction of hepatocellular carcinoma for the presence 
of at least one of the three risk factors indicated above (obesity, 
heavy alcohol drinking, and current smoking) was 51.6%, indi-
cating that in the absence of chronic hepatitis virus infection, about 
half of the hepatocellular carcinoma cases were attributable to 
established risk factors for this disease.
Discussion
In an incidence density-matched case–control study nested within 
the EPIC cohort and comprising 115 histologically confirmed 
incident case patients of hepatocellular carcinoma and 229 control 
subjects, we identified statistically significant associations for 
chronic HBV infection (OR = 9.10), chronic HCV infection (OR = 
13.36), obesity (OR = 2.13), and current smoking at enrollment 
(OR = 4.55). Plausible, but statistically not significant in these data, 
associations were found for high alcohol intake (OR = 1.77) and 
former smoking (OR = 1.98). We also calculated attributable frac-
tions for this Europe-wide cohort. We have estimated that tobacco 
smoking contributed to almost half of the hepatocellular carci-
noma cases in this population (47.6%; ie, 31.2% for current and 
Table 4. Percentages of the hepatocellular carcinoma burden in the European Prospective Investigation into Cancer and nutrition (EPIC) 
population that can be attributed to each or any of the indicated factors, by sex*
Causal exposures Men Women Overall
Overall excluding  
blood donors
Overall excluding  
HBV/HCV positives
Chronic HBV infection 12.2 15.3 13.2 12.1 —
Chronic HCV infection 17.3 29.1 20.9 20.7 —
Former smoking 19.8 8.5 16.4 16.8 13.7
Current smoking 37.1 17.8 31.2 33.3 32.2
Obesity (body mass index ≥30 kg/m2) 16.6 15.1 16.1 15.4 20.9
Heavy ethanol consumption at baseline† 10.3 9.9 10.2 9.7 18.0
Any of the above 67.1 62.7 65.7 65.5 51.6
* HBV = hepatitis B virus; HCV = hepatitis C virus
† Men: alcohol intake: ≥40 g/d; Women, alcohol intake ≥20 g/d.
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16.4% for former smokers), whereas chronic infection with HBV 
or HCV contributed to 13.2% and 20.9%, respectively. We also 
estimated that obesity (BMI ≥ 30 kg/m2) and high regular ethanol 
intake contribute 16.1% and 10.2%, respectively, to the burden of 
the disease. Attributable fractions are not additive, but almost two-
thirds (65.7%, 95% CI = 50.6% to 79.3%) of hepatocellular carci-
nomas in this European population can be accounted for by exposure 
to at least one of the documented strong risk factors for this 
disease.
Large as it is estimated to be, the apparent population attribut-
able fraction for hepatocellular carcinoma is still likely to be an 
underestimate. The EPIC participants are volunteers and, as such, 
are expected to have relatively low prevalence of chronic infection 
of HBV and/or HCV, and to less often be current smokers and 
heavy drinkers than the general population. There is indeed con-
vincing evidence that the prevalence of current smoking (27) and 
heavy drinking (28), though not systematically that of obesity (29), 
is higher in the general adult population of the countries that have 
contributed to the EPIC project than among the control subjects 
in this study. With respect to the prevalence of chronic infection 
with HBV and HCV, the population-based data in the EPIC coun-
tries have been reported to vary from less than 0.5% in northern 
European countries to about 4% in southern European countries 
for both HBV and HCV (30).
With respect to cause-specific population attributable fractions 
(Table 4), these are likely to vary among countries, as the preva-
lence of each of the six indicated exposures also varies (27–30). 
Nevertheless, the order of magnitude indicated in Table 4 does 
reflect the contribution of the established risk factors for hepato-
cellular carcinoma to the burden of the disease in this European 
cohort. With respect to tobacco smoking, we did not take into 
account the duration of the smoking habits, which, at least with 
respect to lung cancer, is a stronger determinant of risk than the 
daily dose of cigarette smoking (31). However, evidence has 
emerged that tobacco smoking may operate mostly in the late stage 
of hepatocellular carcinoma development (32), and the most rele-
vant available metric of exposure to tobacco smoking in our study 
is captured by the information on smoking behavior at enrollment, 
rather than smoking behavior over a lifetime. Our estimate for the 
hepatocellular carcinoma population attributable fraction due to 
alcohol consumption is lower than those reported from other 
studies in economically developed countries (33) and, notably, 
from that reported from a study in the overall EPIC cohort (34). 
In the latter study, the relevant population attributable fraction 
was estimated at 33% (95% CI = 11% to 54%) among men and at 
18% (95% CI = 23% to 38%) among women, for an average 
around 25%. This figure should be compared with our estimates 
of about 10% overall or 18% among hepatitis virus–negative hepa-
tocellular carcinoma case patients. Although the respective confi-
dence intervals are wide and extensively overlapping, the main 
reasons for the higher fractions in other studies, including the 
overall EPIC study, are likely to be that 1) past drinkers, who are 
thought to remain at high risk for hepatocellular carcinoma (33), 
were not specifically studied in our investigation (there were not 
enough control subjects to allow meaningful cross-tabulations by 
current and past drinking habits); 2) calculations in other studies, 
including the overall EPIC study (34), relied on generally higher 
estimates of prevalence of drinking habits in the general popula-
tion, as derived from independent sources (a legitimate approach 
which, however, generates difficulties in the calculation of the 
confidence intervals); and 3) in most other studies, including the 
overall EPIC study, confounding generated by the coexistence of 
chronic infection with HBV or HCV and excessive ethanol intake 
could not be accounted for, as it was in our investigation.
A strength of this study is its reliance on a prospective cohort 
design and the coverage of several European countries with vari-
able prevalent patterns of exposures relevant to hepatocellular 
carcinoma risk. Other strengths of the study include the use of a 
uniform protocol and the centralized laboratory determinations of 
markers of hepatitis B and C infections. Lastly, the sample size can 
be considered adequate for a cohort study in Caucasians, among 
whom hepatocellular carcinoma is a rare tumor.
There are also limitations to this study. We did not have ade-
quate information on possible coexisting cirrhosis, but this condi-
tion is frequently an intermediate in the pathophysiological process 
that links chronic infection with HBV and particularly HCV, as 
well as alcohol drinking, with hepatocellular carcinoma; as such, 
this is a variable that should not be controlled for in the analysis. 
We have not evaluated the role of diabetes mellitus, but we did 
evaluate overweight and obesity. We did not evaluate aflatoxin 
exposure, an established risk factor for hepatocellular carcinoma, 
but this exposure is more relevant for the occurrence of the disease 
in Africa or South Asia rather than in Europe or the United States. 
We did not take into account possible occupational or pharmaceu-
tical exposures linked to liver cancer which, however, appear to be 
rare and mostly related to angiosarcoma rather than hepatocellular 
carcinoma (11). We also did not take into account qualitative 
aspects of the diet, for which a role in hepatocellular carcinoma is 
plausible but not fully documented (35,36); thus, we cannot 
exclude the possibility of some residual confounding by diet or, 
indeed, other unidentified confounding factors. We used broad 
categories for exposure to tobacco smoking, alcohol drinking, and 
obesity, but we have used cutoffs that are widely used in the litera-
ture; moreover, using broad categories is not considered an impor-
tant disadvantage when the focus of the study is the determination 
of the population attributable fraction (37,38). Finally, we could 
not explore possible interactions among these five documented risk 
factors for hepatocellular carcinoma because of power limitations.
In conclusion, we have shown that hepatocellular carcinoma, 
one of the most lethal human cancers, is largely amenable to pri-
mary prevention with existing knowledge and technology. 
Moreover, we have shown that although chronic infection with 
HBV and/or HCV was the strongest risk factor for hepatocellular 
carcinoma, tobacco smoking was responsible for more cases of 
hepatocellular carcinoma than either or both these viruses in this 
population. Finally, our data support existing evidence that heavy, 
although not moderate, alcohol consumption may increase hepa-
tocellular carcinoma risk and that obesity, although not simple 
overweight, also plays a major role in the occurrence of the disease.
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